Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $637.35 million. The enterprise value is $576.10 million.
Important Dates
The last earnings date was Tuesday, March 3, 2026, before market open.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 180.55 million shares outstanding. The number of shares has increased by 25.43% in one year.
| Current Share Class | 177.08M |
| Shares Outstanding | 180.55M |
| Shares Change (YoY) | +25.43% |
| Shares Change (QoQ) | +10.47% |
| Owned by Insiders (%) | 15.05% |
| Owned by Institutions (%) | 48.42% |
| Float | 104.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 137.60 |
| Forward PS | n/a |
| PB Ratio | 5.17 |
| P/TBV Ratio | 5.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 124.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.84, with a Debt / Equity ratio of 0.96.
| Current Ratio | 4.84 |
| Quick Ratio | 4.74 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -146.81% and return on invested capital (ROIC) is -60.39%.
| Return on Equity (ROE) | -146.81% |
| Return on Assets (ROA) | -40.68% |
| Return on Invested Capital (ROIC) | -60.39% |
| Return on Capital Employed (ROCE) | -68.25% |
| Weighted Average Cost of Capital (WACC) | 15.58% |
| Revenue Per Employee | $31,726 |
| Profits Per Employee | -$1.38M |
| Employee Count | 146 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +101.71% in the last 52 weeks. The beta is 2.58, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.58 |
| 52-Week Price Change | +101.71% |
| 50-Day Moving Average | 3.87 |
| 200-Day Moving Average | 3.91 |
| Relative Strength Index (RSI) | 41.58 |
| Average Volume (20 Days) | 2,988,435 |
Short Selling Information
The latest short interest is 27.25 million, so 15.09% of the outstanding shares have been sold short.
| Short Interest | 27.25M |
| Short Previous Month | 28.08M |
| Short % of Shares Out | 15.09% |
| Short % of Float | 26.10% |
| Short Ratio (days to cover) | 9.41 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $4.63 million and -$201.14 million in losses. Loss per share was -$1.35.
| Revenue | 4.63M |
| Gross Profit | -156.00M |
| Operating Income | -208.35M |
| Pretax Income | -201.14M |
| Net Income | -201.14M |
| EBITDA | -201.03M |
| EBIT | -208.35M |
| Loss Per Share | -$1.35 |
Full Income StatementBalance Sheet
The company has $177.68 million in cash and $116.43 million in debt, with a net cash position of $61.25 million or $0.34 per share.
| Cash & Cash Equivalents | 177.68M |
| Total Debt | 116.43M |
| Net Cash | 61.25M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 120.87M |
| Book Value Per Share | 0.68 |
| Working Capital | 143.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$162.56 million and capital expenditures -$4.53 million, giving a free cash flow of -$167.10 million.
| Operating Cash Flow | -162.56M |
| Capital Expenditures | -4.53M |
| Free Cash Flow | -167.10M |
| FCF Per Share | -$0.93 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,498.06% |
| Pretax Margin | -4,342.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.43% |
| Shareholder Yield | -25.43% |
| Earnings Yield | -31.56% |
| FCF Yield | -26.22% |
Analyst Forecast
The average price target for Prime Medicine is $7.56, which is 114.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.56 |
| Price Target Difference | 114.16% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 34.98% |
| EPS Growth Forecast (5Y) | -12.43% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -3.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.8 |
| Piotroski F-Score | 3 |
